Oxymetazoline: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Drug Ratings in...") |
No edit summary |
||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[Decongestant]]; Adrenergic Agonist Agent; Imidazoline derivative | ||
*Dosage Forms: | *Dosage Forms: Solution; Nasal spray | ||
*Routes of Administration: | *Routes of Administration: Intranasal | ||
*Common Trade Names: | *Common Trade Names: 12-Hour Nasal Relieve Spray, Afrin, Mucinex, Distran, Neo-synephrine | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Instill 2-3 sprays for each nostrils twice daily for ≤3 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Children ≥6 years: Instill 2-3 sprays for each nostrils twice daily for ≤3 days | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: Safety during pregnancy has not been studied. | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Not available | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: Not needed | ||
*Pediatric: | *Pediatric: Not needed | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: | *Adult: Not needed | ||
*Pediatric: | *Pediatric: Not needed | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
==Warnings/Precautions== | |||
*Use with caution in patients with hypertension, heart failure or coronary artery disease | |||
*Use with caution in patients with diabetes mellitus | |||
*Use with caution in patients with hyperthyroidism | |||
*Use with caution in patients with benign prostatic hyperplasia | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Rebound nasal congestion may occur with extended use | |||
===Common=== | ===Common=== | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: not available | ||
*Metabolism: | *Metabolism: not available | ||
*Excretion: | *Excretion: not available | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Stimulates α-adrenergic recepter in arterioles of nasal mucosa, produce vasoconstriction | |||
==Comments== | ==Comments== | ||
| Line 41: | Line 50: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ENT]] | |||
Latest revision as of 17:19, 8 February 2022
Administration
- Type: Decongestant; Adrenergic Agonist Agent; Imidazoline derivative
- Dosage Forms: Solution; Nasal spray
- Routes of Administration: Intranasal
- Common Trade Names: 12-Hour Nasal Relieve Spray, Afrin, Mucinex, Distran, Neo-synephrine
Adult Dosing
- Instill 2-3 sprays for each nostrils twice daily for ≤3 days
Pediatric Dosing
- Children ≥6 years: Instill 2-3 sprays for each nostrils twice daily for ≤3 days
Special Populations
- Pregnancy Rating: Safety during pregnancy has not been studied.
- Lactation risk: Not available
Renal Dosing
- Adult: Not needed
- Pediatric: Not needed
Hepatic Dosing
- Adult: Not needed
- Pediatric: Not needed
Contraindications
- Allergy to class/drug
Warnings/Precautions
- Use with caution in patients with hypertension, heart failure or coronary artery disease
- Use with caution in patients with diabetes mellitus
- Use with caution in patients with hyperthyroidism
- Use with caution in patients with benign prostatic hyperplasia
Adverse Reactions
Serious
- Rebound nasal congestion may occur with extended use
Common
Pharmacology
- Half-life: not available
- Metabolism: not available
- Excretion: not available
Mechanism of Action
- Stimulates α-adrenergic recepter in arterioles of nasal mucosa, produce vasoconstriction